Spike (XBB.1.16, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luciferase Reporter)

The Spike (XBB.1.16, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentiviruses are replication incompetent, HIV-based lentiviral particles. They were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the XBB.1.16 mutations, see below for details) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain firefly luciferase driven by a CMV promoter (Figure 1), allowing the spike-mediated cell entry to be measured by luciferase activity. The Spike (XBB.1.16, Omicron Variant) (SARS-CoV-2) pseudoviruses can be used to measure the activity of a neutralizing antibody against the SARS-CoV-2 Omicron XBB.1.16 variant. The Spike Omicron XBB.1.16 pseudoviruses have been validated for use with ACE2-HEK293 target cells (which overexpress ACE2, >BPS Bioscience #79951).